PRS 211096
Alternative Names: PRS-211,096Latest Information Update: 28 Jul 2009
At a glance
- Originator Pharmos Corporation
- Class Analgesics; Cannabinoids
- Mechanism of Action Cannabinoid receptor CB2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Autoimmune disorders; Neuropathic pain; Pain
Most Recent Events
- 06 Jun 2006 No development reported - Preclinical for Autoimmune disorders in USA (unspecified route)
- 06 Jun 2006 No development reported - Preclinical for Neuropathic pain in Israel (unspecified route)
- 06 Jun 2006 No development reported - Preclinical for Pain in Israel (unspecified route)